Beactica Therapeutics AB

STOCKHOLM, June 19, 2023 /PRNewswire/ — Beactica Therapeutics AB, the Swedish precision oncology company, today announced the appointment of Jarl Ulf Jungnelius M.D. to its Board of Directors. The appointment marks another step in Beactica’s strategic plan to become a clinical-stage company. Jarl Ulf Jungnelius M.D. is a licensed medical practitioner and a board-certified oncologist … Read more

STOCKHOLM, June 19, 2023 /PRNewswire/ — Beactica Therapeutics AB, the Swedish precision oncology company, today announced the appointment of Jarl Ulf Jungnelius M.D. to its Board of Directors. The appointment marks another step in Beactica’s strategic plan to become a clinical-stage company. Jarl Ulf Jungnelius M.D. is a licensed medical practitioner and a board-certified oncologist … Read more

STOCKHOLM, May 16, 2023 /PRNewswire/ — Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023. The conference will take place on May 23-35, 2023, in Boston, Massachusetts. Dr Peter Brandt, Head of Chemistry, will … Read more

STOCKHOLM, May 16, 2023 /PRNewswire/ — Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023. The conference will take place on May 23-35, 2023, in Boston, Massachusetts. Dr Peter Brandt, Head of Chemistry, will … Read more